Search Results - Daniel Slade

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial by Amit Patel, Kristian Brock, Daniel Slade, Claire Gaunt, Anthony Kong, Hisham Mehanna, Lucinda Billingham, Piers Gaunt

    Published in BMC Medical Research Methodology (2024-01-01)
    Get full text
    Article


  2. 2

    Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study proto... by Sarah Johnson, Geoff Shenton, Ruth Plummer, Joshua Savage, Gareth J Veal, Julie Irving, Lucinda Billingham, Pamela Kearns, Daniel Slade, Tobias Menne, Britta Vormoor, Josef Vormoor

    Published in BMJ Open (2022-03-01)
    Get full text
    Article


  3. 3

    Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial by Katherine Arndtz, Yung-Yi Chen, Anna Rowe, Victoria Homer, Amanda Kirkham, Jessica Douglas-Pugh, Daniel Slade, Douglas Thorburn, Eleanor Barnes, Guruprasad Aithal, Philip Newsome, David Smith, David Adams, Christopher Weston, Gideon Hirschfield

    Published in Efficacy and Mechanism Evaluation (2022-03-01)
    Get full text
    Article


  4. 4

    CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults by Dhruv Parekh, Simon Gates, Julian Bion, Tonny Veenith, Matthew Rowland, Tony Whitehouse, Anna Rowe, Pamela Kearns, Benjamin A. Fisher, Daniel Slade, Rowena Sharpe, David R. Thickett, James Scriven, Sarah J. Bowden, Joshua S. Savage, Duncan Richards

    Published in BMJ Open (2021-11-01)
    Get full text
    Article


Search Tools: